文献速递主动脉疾病

编辑精选——局限于升胸主动脉的血管内修复结局:系统综述与荟萃分析

Editor's Choice - Outcomes of Endovascular Repair Confined to the Ascending Thoracic Aorta: A Systematic Review and Meta-Analysis.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2024-11-08

该系统综述与荟萃分析纳入94项研究共259例患者,评估局限于升主动脉的胸主动脉腔内修复(a-TEVAR)的结局。住院死亡率为7.3%(95%CI 4.7-11.2%),30天死亡率为7.7%(95%CI 5.1-11.6%),随访期间总死亡率为17.0%(95%CI 12.9-22.0%),GRADE证据确定性均为极低。作者认为a-TEVAR在高风险患者中似乎技术可行,但文献异质性大,需就使用时机与方法达成共识并研发升主动脉专用腔内移植物。

要点

  • a-TEVAR住院死亡率7.3%、30天死亡率7.7%、随访总死亡率17.0%,GRADE证据确定性极低。
  • A型主动脉夹层住院与30天死亡率分别为12.4%和13.3%,假性动脉瘤均为4.0%。
  • 再手术率13.1%,共报告88例并发症;最常见适应证为A型夹层(43.6%)和假性动脉瘤(38.6%)。

核心结论

  • 尽管文献异质性大且GRADE证据确定性极低,a-TEVAR在高风险患者中似乎技术可行。
  • 作者认为需要就何时以及如何使用a-TEVAR达成共识,并需要一种专用于升主动脉的腔内移植物。

研究设计与样本

  • 系统综述与荟萃分析,遵循PRISMA声明,系统检索MEDLINE、Web of Science和Scopus(PROSPERO ID:CRD42023440826),纳入截至2024年1月1日的文献。
  • 纳入报告无附加主动脉上血管处理的a-TEVAR结局的合格研究,共94项研究(19项队列研究,75项病例报告或系列),报告259例患者(57.8%为男性)。
  • 质量评估工具为ROBINS-I和Joanna Briggs Institute Critical Appraisal Checklist,并对主要结局进行GRADE证据确定性分析。
  • 主要结局为死亡,采用比例荟萃分析,以均数和95%CI报告主要结局。

主要发现

  • 患者平均年龄69.1岁(95%CI 65.0-73.1),平均随访19.6个月(95%CI 14.5-24.6);最常见合并症为既往心脏或胸部手术(n=191)。
  • a-TEVAR最常见适应证为A型主动脉夹层(43.6%)和假性动脉瘤(38.6%),52.1%为紧急a-TEVAR;最常用支架移植物为Gore(44.5%)、Cook(23.5%)和Medtronic(17.0%)。
  • 住院死亡率7.3%(95%CI 4.7-11.2%),30天死亡率7.7%(95%CI 5.1-11.6%),随访期间总死亡率17.0%(95%CI 12.9-22.0%);GRADE显示所有结局证据确定性极低。
  • 共报告88例并发症,再手术率13.1%(95%CI 9.5-17.8%)。
  • A型夹层住院死亡率12.4%(95%CI 7.5-19.7%,n=14)、30天死亡率13.3%(95%CI 8.2-20.8%,n=15);假性动脉瘤住院与30天死亡率均为4.0%(95%CI 1.6-9.8%,n=4)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 文献异质性大且GRADE证据确定性极低。
  • 作者认为需要就何时以及如何使用a-TEVAR达成共识,并需要一种专用于升主动脉的腔内移植物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: High risk, inoperable patients with ascending aortic disease are increasingly managed with thoracic endovascular aortic repair (TEVAR). The aim of this study was to assess the available literature on TEVAR confined to the ascending aorta (a-TEVAR), describing study and patient characteristics, procedural and stent graft details, and outcomes. DATA SOURCES: This was a systematic review and meta-analysis. MEDLINE, Web of Science, and Scopus were systematically searched for eligible studies reporting on outcomes after a-TEVAR (PROSPERO ID: CRD42023440826). Eligible studies reported outcomes after a-TEVAR without adjunctive supra-aortic vessel treatment. REVIEW METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was followed. The ROBINS-I and Joanna Briggs Institute Critical Appraisal Checklist were used as quality assessment tools. A Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence certainty analysis was performed for the main outcomes. The main outcome was death. A proportional meta-analysis was performed with a mean and 95% confidence interval (CI) for the main outcomes. All articles were included up to 1 January 2024. RESULTS: Ninety four studies were included (19 cohort studies, 75 case reports or series), reporting on 259 patients (57.8% male). The mean age was 69.1 (95% CI 65.0 - 73.1) years and mean follow up 19.6 (95% CI 14.5 - 24.6) months. The most common comorbidity was prior cardiac or thoracic surgery (n = 191). The most frequent indications for a-TEVAR (52.1% urgent a-TEVAR) were type A aortic dissection (43.6%) and pseudoaneurysm (38.6%). The most commonly deployed stent grafts were Gore (44.5%), Cook (23.5%), and Medtronic (17.0%). The in hospital mortality rate was 7.3% (95% CI 4.7 - 11.2%), 30 day mortality rate 7.7% (95% CI 5.1 - 11.6%), and overall mortality rate 17.0% (95% CI 12.9 - 22.0%) during follow up. GRADE showed very low evidence certainty for all outcomes. Eighty eight complications were reported and there was a re-operation rate of 13.1% (95% CI 9.5 - 17.8%). In hospital and 30 day mortality rates for type A dissection were 12.4% (95% CI 7.5 - 19.7%) (n = 14) and 13.3% (95% CI 8.2 - 20.8%) (n = 15), respectively, and for pseudoaneurysm 4.0% (95% CI 1.6 - 9.8%) (n = 4) and 4.0% (95% CI 1.6 - 9.8) (n = 4), respectively. CONCLUSION: Despite heterogeneous literature and very low GRADE evidence certainty, a-TEVAR seems technically feasible in high risk patients. In addition, there is need for a consensus on when and how to use a-TEVAR and a need for a specific endograft for use in the ascending aorta.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. de Kort JF, Mandigers TJ, Bissacco D, et al. Editor's Choice - Outcomes of Endovascular Repair Confined to the Ascending Thoracic Aorta: A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg. 2024. PMID: 39522585. doi:10.1016/j.ejvs.2024.10.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。